- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,130 | 20.06.24 17:35:33 | +0,440 | +0,50% | 0,000 | 0,000 | 86,830 | 87,690 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.041,550 | 20.06.24 20:27:25 | +2,440 | +0,23% | 1.040,680 | 1.042,270 | 1.038,440 | 1.039,110 |
